Evaluation of a Unani formulation, in diabetic peripheral neuropathy: A randomized single blind standard controlled study Asian Journal of Medical and Clinical Sciences Short Communication

To evaluate the efficacy of a Unani formulation in the management of Diabetic peripheral neuropathy in patients of type 2 diabetes mellitus.A randomized single blind standard controlled trial was carried out at National institute of Unani medicine, Bangalore, India. After ethical clearance, total 41 diagnosed patients of DPN were screened, two excluded, remaining 39 were randomly allocated to test(Group A) and control(Group B) groups, as nine dropped out, twenty patients in test and 10 patients in control group completed full course of treatment. Group A was given Habbe Azaraqi, 500 mg in tablet form, twice a day, whereas patients of group B received Methycobalamine, 500 mcg once a day for a period of 45 days. In order to maintain glycaemic index, Glibenclamide 5mg twice a day was given in both groups for the same duration. An informed consent was taken from each patient. The subjective parameters were assessed fortnightly, while in objective parameters TCNS fortnightly and VPT was assessed before and after treatment.The test drug exhibited statistically significant improvement in subjective parameters in intra group comparison, whereas it was not significant in inter group comparison. In objective parameters TCNS and VPT both were statistically significant in intra group comparison (P<0.05), while TCNS was also significant in inter group comparison (P<0.005) in test with respect to control, but VPT was not significant in inter group comparison.The study reveals that test drug is effective and safe in the management of diabetic peripheral neuropathy. Further, it may be recommended for delaying complications of diabetic peripheral neuropathy